vs
FIRST ADVANTAGE CORP（FA）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
FIRST ADVANTAGE CORP的季度营收约是Orthofix Medical Inc.的1.9倍（$420.0M vs $219.9M），FIRST ADVANTAGE CORP净利率更高（0.8% vs -1.0%，领先1.8%），FIRST ADVANTAGE CORP同比增速更快（36.8% vs 2.0%），FIRST ADVANTAGE CORP自由现金流更多（$62.2M vs $16.8M），过去两年FIRST ADVANTAGE CORP的营收复合增速更高（57.5% vs 8.0%）
First Advantage是全球领先的劳动力筛查与背景验证服务提供商，服务覆盖科技、医疗、金融、零售、制造等多个行业的各规模客户，助力企业管控雇佣风险、满足合规要求，打造安全可信的工作环境。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FA vs OFIX — 直观对比
营收规模更大
FA
是对方的1.9倍
$219.9M
营收增速更快
FA
高出34.8%
2.0%
净利率更高
FA
高出1.8%
-1.0%
自由现金流更多
FA
多$45.3M
$16.8M
两年增速更快
FA
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $420.0M | $219.9M |
| 净利润 | $3.5M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 10.7% | 0.2% |
| 净利率 | 0.8% | -1.0% |
| 营收同比 | 36.8% | 2.0% |
| 净利润同比 | 103.5% | 92.4% |
| 每股收益（稀释后） | $0.03 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FAOFIX
| Q4 25 | $420.0M | $219.9M | ||
| Q3 25 | $409.2M | $205.6M | ||
| Q2 25 | $390.6M | $203.1M | ||
| Q1 25 | $354.6M | $193.6M | ||
| Q4 24 | $307.1M | $215.7M | ||
| Q3 24 | $199.1M | $196.6M | ||
| Q2 24 | $184.5M | $198.6M | ||
| Q1 24 | $169.4M | $188.6M |
净利润FAOFIX
| Q4 25 | $3.5M | $-2.2M | ||
| Q3 25 | $2.6M | $-22.8M | ||
| Q2 25 | $308.0K | $-14.1M | ||
| Q1 25 | $-41.2M | $-53.1M | ||
| Q4 24 | $-100.4M | $-29.1M | ||
| Q3 24 | $-8.9M | $-27.4M | ||
| Q2 24 | $1.9M | $-33.4M | ||
| Q1 24 | $-2.9M | $-36.0M |
毛利率FAOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率FAOFIX
| Q4 25 | 10.7% | 0.2% | ||
| Q3 25 | 10.3% | -8.3% | ||
| Q2 25 | 9.7% | -7.9% | ||
| Q1 25 | 2.1% | -25.2% | ||
| Q4 24 | -26.3% | -5.3% | ||
| Q3 24 | 4.6% | -9.6% | ||
| Q2 24 | 5.4% | -12.5% | ||
| Q1 24 | -0.4% | -15.6% |
净利率FAOFIX
| Q4 25 | 0.8% | -1.0% | ||
| Q3 25 | 0.6% | -11.1% | ||
| Q2 25 | 0.1% | -6.9% | ||
| Q1 25 | -11.6% | -27.4% | ||
| Q4 24 | -32.7% | -13.5% | ||
| Q3 24 | -4.4% | -13.9% | ||
| Q2 24 | 1.0% | -16.8% | ||
| Q1 24 | -1.7% | -19.1% |
每股收益（稀释后）FAOFIX
| Q4 25 | $0.03 | $-0.05 | ||
| Q3 25 | $0.01 | $-0.57 | ||
| Q2 25 | $0.00 | $-0.36 | ||
| Q1 25 | $-0.24 | $-1.35 | ||
| Q4 24 | $-0.67 | $-0.76 | ||
| Q3 24 | $-0.06 | $-0.71 | ||
| Q2 24 | $0.01 | $-0.88 | ||
| Q1 24 | $-0.02 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $240.0M | $82.0M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $1.3B | $450.0M |
| 总资产 | $3.8B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.61× | — |
8季度趋势，按日历期对齐
现金及短期投资FAOFIX
| Q4 25 | $240.0M | $82.0M | ||
| Q3 25 | $216.8M | $62.9M | ||
| Q2 25 | $184.3M | $65.6M | ||
| Q1 25 | $172.0M | $58.0M | ||
| Q4 24 | $168.7M | $83.2M | ||
| Q3 24 | $307.4M | $30.1M | ||
| Q2 24 | $269.6M | $26.4M | ||
| Q1 24 | $246.0M | $27.0M |
总债务FAOFIX
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $157.2M | ||
| Q2 25 | $2.1B | $157.0M | ||
| Q1 25 | $2.2B | $156.9M | ||
| Q4 24 | $2.2B | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益FAOFIX
| Q4 25 | $1.3B | $450.0M | ||
| Q3 25 | $1.3B | $442.5M | ||
| Q2 25 | $1.3B | $458.3M | ||
| Q1 25 | $1.3B | $458.3M | ||
| Q4 24 | $1.3B | $503.1M | ||
| Q3 24 | $920.7M | $525.9M | ||
| Q2 24 | $913.3M | $546.0M | ||
| Q1 24 | $907.7M | $570.3M |
总资产FAOFIX
| Q4 25 | $3.8B | $850.6M | ||
| Q3 25 | $3.9B | $832.6M | ||
| Q2 25 | $3.9B | $837.2M | ||
| Q1 25 | $3.9B | $823.1M | ||
| Q4 24 | $3.9B | $893.3M | ||
| Q3 24 | $1.7B | $867.9M | ||
| Q2 24 | $1.6B | $882.0M | ||
| Q1 24 | $1.6B | $906.0M |
负债/权益比FAOFIX
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.64× | 0.36× | ||
| Q2 25 | 1.65× | 0.34× | ||
| Q1 25 | 1.69× | 0.34× | ||
| Q4 24 | 1.66× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $65.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $62.2M | $16.8M |
| 自由现金流率自由现金流/营收 | 14.8% | 7.6% |
| 资本支出强度资本支出/营收 | 0.9% | 4.9% |
| 现金转化率经营现金流/净利润 | 19.01× | — |
| 过去12个月自由现金流最近4个季度 | $188.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FAOFIX
| Q4 25 | $65.9M | $27.7M | ||
| Q3 25 | $72.4M | $12.4M | ||
| Q2 25 | $37.3M | $11.6M | ||
| Q1 25 | $19.5M | $-18.4M | ||
| Q4 24 | $-85.7M | $23.7M | ||
| Q3 24 | $43.5M | $11.7M | ||
| Q2 24 | $32.0M | $9.0M | ||
| Q1 24 | $38.3M | $-18.6M |
自由现金流FAOFIX
| Q4 25 | $62.2M | $16.8M | ||
| Q3 25 | $71.2M | $2.5M | ||
| Q2 25 | $36.1M | $4.5M | ||
| Q1 25 | $19.0M | $-25.1M | ||
| Q4 24 | $-86.0M | $15.2M | ||
| Q3 24 | $43.1M | $6.3M | ||
| Q2 24 | $31.4M | $-360.0K | ||
| Q1 24 | $38.0M | $-29.1M |
自由现金流率FAOFIX
| Q4 25 | 14.8% | 7.6% | ||
| Q3 25 | 17.4% | 1.2% | ||
| Q2 25 | 9.2% | 2.2% | ||
| Q1 25 | 5.4% | -13.0% | ||
| Q4 24 | -28.0% | 7.0% | ||
| Q3 24 | 21.6% | 3.2% | ||
| Q2 24 | 17.0% | -0.2% | ||
| Q1 24 | 22.4% | -15.4% |
资本支出强度FAOFIX
| Q4 25 | 0.9% | 4.9% | ||
| Q3 25 | 0.3% | 4.8% | ||
| Q2 25 | 0.3% | 3.5% | ||
| Q1 25 | 0.1% | 3.5% | ||
| Q4 24 | 0.1% | 4.0% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.4% | 4.7% | ||
| Q1 24 | 0.2% | 5.6% |
现金转化率FAOFIX
| Q4 25 | 19.01× | — | ||
| Q3 25 | 27.91× | — | ||
| Q2 25 | 121.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 17.22× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FA
| First Advantage Americas | $209.9M | 50% |
| Sterling | $185.9M | 44% |
| First Advantage International | $24.2M | 6% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
